Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Review fee comparisons across wide market index funds to find the lowest-cost option for retirement. Practical guidance to reduce recurring expenses.
28,610 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
PetSmart confirms the closure of its lone San Francisco location as online shopping reshapes the pet retail landscape...
Bank Of America upgrades TripAdvisor to Buy, signaling potential value from Viator and TheFork as Starboard Value exp...
Binance reports that about 70% of EU withdrawals went to self-custody wallets after the MiCA deadline, with 30% stayi...
In a high-stakes Senate hearing, Treasury Secretary Scott Bessent denies a looming $14 billion windfall for Iran from...
XRP and ETH traders are driving a surge in fear of missing out, lifting sentiment to multi-week highs even as prices ...
A Qatar-linked LNG carrier crossed Hormuz, the first export through the strait since the war intensified. The move co...
A high-profile insider move by Pinterest’s leadership drew attention from investors. This deep dive explains what the...
MeridianLink unveils MeridianLink Intelligence within its MeridianLink One platform, introducing the Millie AI agent ...
Quantum investing is no longer a dream. This practical guide weighs D-Wave Quantum’s potential, the risks, and steps ...
A university dean warns that AI's push for efficiency could erase entry-level roles for young workers, even as they d...
Apple hits a fresh 52-week high as Services revenue climbs and iPhone demand remains strong. The move fuels a buy, ho...